ANEW Medical, Inc. Acquires Innovative Technology
ANEW MEDICAL, INC. (“ANEW” or the “Company”) (Nasdaq: WENA) has announced that it has signed an exclusive worldwide licensing agreement with Transfertech Sherbrooke (“TTS”) for Nanoject. This innovative technology is a needle-free, freeze-dried nanopowder autoinjector designed for administering medicines and vaccines.
Tackling Needle Phobia
Needle phobia is a widespread issue that affects both adults and children, often leading to anxiety during injections and making it difficult for patients to stick to medical protocols. Conventional methods such as creams, patches, and liquid autoinjectors can be costly and come with various formulation limitations, underscoring the urgent need for better alternatives.
How Nanoject Works
The patented Nanoject delivery system employs a pressure-driven flow from a miniature shock tube, enabling it to rapidly inject nano-sized or micron-sized medication particles into the skin at speeds of up to 600 meters per second. This allows for effective delivery into both intradermal and subcutaneous tissues.
Insights from ANEW’s Leadership
Dr. Joseph Sinkule, the CEO of ANEW, shared his excitement about this technology, stating, “ANEW is continuously exploring opportunities to generate near-term revenue while leveraging our expertise to develop new patented technologies that are critically needed for treating human diseases. The nanoparticle injector signifies a major breakthrough in drug delivery, effectively addressing challenges related to storage, stability, and dosage.”
Collaborative Efforts for Development and Distribution
Jeffrey LeBlanc, ANEW's CFO, mentioned that the company is working on a low-cost, needle-free delivery method aimed at enhancing the quality of life for patients across various healthcare sectors, including pain management and vaccination. They intend to partner with pharmaceutical companies to innovate drugs that are protected by patents.
Leadership of the Nanoject Business Unit
Eric Boyd has been appointed to lead operations and partnerships within the Nanoject division. He will collaborate closely with TTS and Dr. Martin Brouillette’s lab at Université de Sherbrooke. Boyd highlighted the vast number of injections performed annually, which drives the need for more patient-friendly solutions, particularly emphasizing the suitability of this technology for self-administration by patients.
About ANEW Medical, Inc.
ANEW MEDICAL, INC. is dedicated to the development of technology and medical products aimed at creating therapeutics and diagnostics for a range of chronic and life-threatening diseases. Their portfolio includes proprietary gene therapy programs and clinical-stage projects targeting cancer and autoimmune disorders, alongside the Nanoject system.
Contact Information
For further inquiries, please reach out to:
Investor Relations
Email: IR@anewmeds.com
Frequently Asked Questions
What is the Nanoject technology?
Nanoject is an innovative needle-free delivery system designed to administer medications through the skin using a freeze-dried nanopowder without the need for needles.
Why is needle-free technology important?
Needle-free technology addresses the challenges of needle phobia, minimizes pain, and reduces the risk of infection and medical waste that can arise from traditional injection methods.
What therapeutic areas will ANEW focus on with Nanoject?
ANEW intends to target various therapeutic areas, including pain management, fertility treatments, growth hormones, erectile dysfunction, and vaccines.
Who manages the Nanoject business unit?
Eric Boyd has been appointed as the Managing Director of the Nanoject business unit, where he oversees its operations and partnerships.
What is the long-term vision for ANEW Medical, Inc.?
ANEW aims to drive innovation in therapeutics and diagnostics while expanding their product offerings and improving patient care through advanced technologies.
